Point of Care Diagnostics Market

Point of Care Diagnostics Market Analysis and Forecast by Fact.MR

• The Point of Care Diagnostics Market is expected to grow from USD 47.8 billion in 2026 to USD 94.1 billion by 2036, at a 7.0% CAGR.
• driven by expanding institutional procurement, rising clinical adoption across acute and chronic care settings, and integration of advanced technology platforms into established care delivery workflows, with glucose monitoring systems accounting for 64.8% share and acute care diagnostics contributing 58.3% share
• as organizations prioritize operational efficiency, clinical accuracy, and regulatory compliance.

Summary of Point of Care Diagnostics Market

• Market Snapshot
  • In 2025, the global Point of Care Diagnostics Market was valued at approximately USD 44.7 billion.
  • The market is estimated to reach USD 47.8 billion in 2026 and is projected to attain USD 94.1 billion by 2036.
  • The point of care diagnostics market is likely to expand at a CAGR of 7.0% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 46.3 billion between 2026 and 2036.
  • Glucose Monitoring Systems accounts for 64.8% of product segment share in 2026.
  • India (7.8%) and China (7.6%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Expanding chronic disease prevalence, particularly diabetes and cardiovascular conditions, is increasing demand for bedside glucose monitoring, cardiac marker testing, and coagulation analysis systems.
  • CLIA waiver approvals for molecular respiratory and infectious disease panels are enabling decentralized testing in urgent care clinics, retail pharmacies, and primary care practices.
  • Reimbursement expansion for remote physiological monitoring, including new CPT codes covering connected diagnostic devices, is widening the financially viable use cases for point-of-care platforms.
  • Increasing procurement by government health programs in India, China, and sub-Saharan Africa for rapid infectious disease and malaria testing is creating high-volume demand in emerging markets.
  • Miniaturization of biosensor, microfluidic, and molecular amplification technologies is enabling multi-analyte testing on portable platforms suited for decentralized care delivery.
• Product and Segment View
  • Glucose Monitoring Systems account for 64.8% of the product segment in 2026, led by broad institutional adoption and established procurement patterns.
  • Acute Care Diagnostics represents 58.3% of the application segment in 2026, reflecting sustained demand across clinical and institutional settings.
  • Key segmentation includes:
    • Product: Glucose Monitoring Systems, Infectious Disease Testing Systems, Cardiac Marker Testing Systems, Hematology Testing Systems
    • Application: Acute Care Diagnostics, Chronic Disease Management, Infectious Disease Detection, Maternal & Pediatric Testing
    • End Use: Hospitals & Clinics, Homecare Settings, Ambulatory Care Centers, Research & Academic Institutes
  • These systems enable:
    • Standardized clinical workflows across multi-site institutional networks
    • Improved diagnostic accuracy and treatment response monitoring
    • Expanded accessibility in decentralized and resource-limited care settings
• Geography and Competitive Outlook
  • North America accounts for a leading share of global demand, supported by established institutional infrastructure, regulatory clarity, and high per-capita healthcare spending.
  • Europe maintains steady demand, with Germany and the UK supported by structured compliance requirements and hospital modernization programs.
  • Asia Pacific is the fastest-growing region, with India and China expanding capacity through government health programs and private investment.
  • India (7.8%) and China (7.6%) are the fastest-growing country markets through 2036.
  • Key companies include Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens Healthineers (Siemens AG), Danaher Corporation (Beckman Coulter, Cepheid, Radiometer), Thermo Fisher Scientific Inc., BD (Becton, Dickinson and Company), bioMérieux SA, QuidelOrtho.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The point of care diagnostics landscape is shifting from volume-driven procurement toward value-based purchasing, where institutions evaluate total cost of ownership, clinical integration capability, and service network coverage alongside unit pricing. Companies that combine reliable product performance with digital connectivity and responsive after-sales support are positioned to capture a larger share of institutional budgets. The most commercially significant growth pockets over the forecast period are concentrated in markets where healthcare infrastructure investment is creating new facility demand alongside replacement cycles in established networks.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Chronic disease burden, including 537 million adults living with diabetes globally, sustains long-term demand for continuous glucose monitoring, hemoglobin testing, and cardiac biomarker systems.
• Infectious disease outbreak preparedness programs and WHO prequalification of new rapid diagnostic tests are generating institutional procurement volumes in emerging markets.
• Connected diagnostic platforms that transmit results to electronic health records and enable remote clinician review are shifting buyer preference toward higher-value, subscription-linked systems.

Key Market Constraints

• Reagent cold-chain requirements and network coverage gaps in remote regions limit deployment of molecular and cartridge-based point-of-care testing platforms.
• Reimbursement uncertainty for newer point-of-care analytes constrains adoption in markets where payer coverage determines institutional purchasing decisions.
• Quality assurance challenges with decentralized testing, including user error rates and result variability, limit regulatory acceptance for certain clinical applications.

Key Opportunity Areas

• Over-the-counter continuous glucose monitoring approvals, such as Dexcom Stelo, are opening a consumer health testing channel previously restricted to prescription-based medical devices.
• Multi-analyte cartridge platforms capable of running combined respiratory, cardiac, and metabolic panels from a single sample are increasing clinical value per test event.
• Government-funded diagnostic stockpiling programs for pandemic preparedness are creating bulk procurement opportunities for rapid antigen and molecular testing platforms.

Segment-wise Analysis of the Point of Care Diagnostics Market

• Glucose Monitoring Systems hold 64.8% of the product segment in 2026, supported by broad institutional procurement and established clinical adoption.
• Acute Care Diagnostics represents 58.3% of the application segment in 2026, reflecting high-volume demand across acute and institutional care settings.
• Hospitals & Clinics account for 69.2% of the end use segment, reflecting concentration of procurement within multi-specialty institutional networks.

The point of care diagnostics market is segmented by product, application, end use, technology, formulation, distribution channel, and region. Glucose Monitoring Systems lead the market by value in 2026 due to their established clinical role, broad institutional adoption, and steady procurement cycles across both public and private healthcare systems.

Which Product Segment Dominates the Point of Care Diagnostics Market?

Glucose Monitoring Systems are expected to account for 64.8% of the product segment in 2026. This leadership is supported by sustained procurement across hospital systems, established clinical protocols, and broad regulatory acceptance in major markets. These products serve as the primary functional category within institutional care workflows, and their demand is directly tied to patient volumes and clinical throughput.

The segment benefits from ongoing government investment in healthcare infrastructure, where standardized equipment configurations include glucose monitoring systems as core components. Replacement cycles for aging systems in developed markets further reinforce volume stability, while new facility construction in emerging markets generates incremental demand.

Which Application Segment Dominates the Point of Care Diagnostics Market?

Acute Care Diagnostics is expected to lead the application segment with a 58.3% share of market value in 2026. This segment captures the highest volume of institutional demand, reflecting the concentration of clinical activity in acute care, emergency response, and specialized treatment settings.

Demand is supported by continued expansion of institutional capacity in both mature and developing healthcare systems. The segment absorbs a growing share of equipment and technology spending as institutions invest in higher-specification systems to meet updated regulatory and accreditation requirements.

Which Technology Trend is Shaping the Next Phase of Growth in the Point of Care Diagnostics Market?

Biosensor Technology represent an evolving part of the point of care diagnostics market landscape. Their adoption is accelerating as institutions seek higher-specification, digitally integrated equipment that supports real-time data capture, connectivity, and workflow optimization. This shift reflects broader changes in institutional procurement behavior, where buyers increasingly evaluate technology integration capability alongside core clinical performance.

The transition toward connected, data-enabled platforms is creating a premium growth layer within the market. Institutions investing in digital infrastructure are prioritizing equipment that supports remote monitoring, centralized data management, and interoperability with existing hospital information systems. As these capabilities become standard procurement criteria, they are positioned to influence a growing share of total capital spending per facility.

Regional Outlook Across Key Markets

• India leads growth at 7.8%, supported by Ayushman Bharat procurement of rapid glucose and infectious disease testing at primary health centers, tier-2 city infrastructure gaps, and government diagnostic stockpiling programs.
• China at 7.6% benefits from hospital modernization budgets, provincial health procurement tenders, and domestic biosensor manufacturing growth creating scale demand for connected diagnostic platforms.
• North America leads the market, supported by Medicare CPT code expansion for remote monitoring, CLIA-waived molecular panel approvals, and retail health clinic proliferation across the United States.
• Europe shows steady growth, shaped by EU IVDR compliance timelines, decentralized primary care models in Germany and France, and NHS adoption of rapid respiratory and cardiac testing.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

India Point of Care Diagnostics Market Analysis

The India Point of Care Diagnostics Market is projected to grow at a CAGR of 7.8% through 2036. Ayushman Bharat coverage expansion and National Health Mission procurement are driving volume adoption of rapid glucose, infectious disease, and cardiac marker testing at primary health centers across India.

• Ayushman Bharat expansion and National Health Mission procurement are driving volume adoption of glucose monitoring, rapid infectious disease testing, and cardiac marker systems in primary health centers.
• Tier-2 and tier-3 city healthcare infrastructure gaps create demand for portable, battery-operated point-of-care platforms that function without centralized laboratory support.

Point of Care Diagnostics Opportunity Outlook in China

The China Point of Care Diagnostics Market is projected to grow at a CAGR of 7.6% through 2036. Hospital modernization budgets, provincial health procurement tenders, and domestic biosensor manufacturing growth are generating large-scale demand for point-of-care diagnostic platforms in China.

• Hospital modernization budgets and provincial health department procurement tenders generate large-scale demand for biosensor-based glucose monitoring and rapid molecular diagnostic systems.
• Domestic diagnostic device manufacturers are expanding product portfolios and gaining share through competitive pricing and local distribution networks.

Market Outlook for Point of Care Diagnostics in South Korea

The South Korea Point of Care Diagnostics Market is projected to grow at a CAGR of 7.5% through 2036. HIRA reimbursement coverage for point-of-care testing and advanced hospital IT infrastructure create favorable conditions for connected diagnostic platform adoption in South Korea.

• HIRA reimbursement coverage for point-of-care testing and advanced hospital IT integration create favorable adoption conditions for connected diagnostic platforms.
• Government R&D support for diagnostic technology and strong domestic OEM positions in biosensor manufacturing sustain innovation-driven market growth.

Germany Point of Care Diagnostics Demand Trends

The Germany Point of Care Diagnostics Market is projected to grow at a CAGR of 7.4% through 2036. EU IVDR compliance timelines and decentralized primary care delivery models are shaping institutional procurement specifications for rapid diagnostic systems in Germany.

• EU IVDR compliance timelines and GKV reimbursement evidence requirements shape institutional procurement specifications for point-of-care diagnostic systems.
• Primary care physician adoption of rapid testing platforms, supported by decentralized healthcare delivery models, expands demand beyond traditional hospital laboratory channels.

Point of Care Diagnostics Growth Assessment in USA

The USA Point of Care Diagnostics Market is projected to grow at a CAGR of 7.3% through 2036. Medicare CPT code expansions for remote physiological monitoring, CLIA-waived molecular testing approvals, and retail health clinic proliferation are widening the addressable market for point-of-care diagnostics in the United States.

• Medicare CPT code expansions for remote physiological monitoring and CLIA-waived molecular testing are widening reimbursable use cases for point-of-care diagnostics.
• Established retail health clinic networks and urgent care center proliferation create high-volume demand channels for rapid antigen, cardiac, and glucose testing systems.

Competitive Benchmarking and Company Positioning

Point of Care Diagnostics Market Analysis By Company

• Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens Healthineers (Siemens AG), Danaher Corporation (Beckman Coulter, Cepheid, Radiometer) hold strong positions in the global point of care diagnostics market through broad product portfolios, established distribution networks, and institutional procurement relationships.
• Thermo Fisher Scientific Inc., BD (Becton, Dickinson and Company), bioMérieux SA, QuidelOrtho participate meaningfully across specific segments, geographies, and price tiers, with competition shaped by clinical performance, regulatory compliance, and service coverage.
• Technology integration, digital connectivity, and after-sales service quality create competitive differentiation, particularly in institutional procurement where total cost of ownership influences purchasing decisions.

The competitive landscape is moderately fragmented, with a mix of established global manufacturers and regional specialists. Abbott Laboratories, with a 33.8% share, leads through broad product coverage, institutional relationships, and geographic reach. Below the leading positions, Thermo Fisher Scientific Inc., BD (Becton, Dickinson and Company), bioMérieux SA compete through pricing, product specialization, and regional distribution strength.

Strategic priorities across the market include expanding digitally connected product portfolios, strengthening institutional service networks, improving regulatory approval timelines, and widening reach through direct-to-institution and e-commerce distribution channels.

Key Companies in the Point of Care Diagnostics Market

• Abbott Laboratories, Hoffmann-La Roche Ltd., Siemens Healthineers (Siemens AG), Danaher Corporation (Beckman Coulter, Cepheid, Radiometer) are among the leading participants in the point of care diagnostics market, supported by broad product portfolios, global distribution, and established institutional procurement relationships.
• Thermo Fisher Scientific Inc., BD (Becton, Dickinson and Company), bioMérieux SA, QuidelOrtho hold established positions across specific product segments and regional markets, supported by clinical performance and channel coverage.
• Johnson & Johnson Services Inc., Nova Biomedical, Cardinal Health Inc., Bio-Rad Laboratories Inc. continue to compete through focused product offerings, price-point coverage, and niche specialization in specific clinical applications.

Recent Industry Developments

• Roche, FDA Clearance / Molecular Bordetella Assay (December 2025)
  • Roche received FDA 510(k) clearance and a CLIA waiver for its first molecular point-of-care assay for Bordetella infections on the cobas Liat system, delivering results in approximately 15 minutes.
• Roche, Point-of-Care STI Assay Launch (February 2025)
  • Roche launched two point-of-care molecular assays for sexually transmitted diseases on the cobas Liat platform, expanding decentralized sexual health diagnostics in clinical settings.
• Abbott, i-STAT TBI Cartridge FDA Clearance (2025)
  • Abbott received FDA clearance for the i-STAT TBI cartridge, a whole-blood-based point-of-care diagnostic for assessing traumatic brain injury at the bedside, extending rapid diagnostics beyond traditional laboratory settings.
• Phase Scientific, FebriDx Test U.S. Launch (July 2025)
  • Phase Scientific launched the FebriDx test in the United States, expanding its Indicaid respiratory portfolio with a rapid point-of-care tool for differentiating bacterial and viral infections.

Leading Companies Shaping the Point of Care Diagnostics Market

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Siemens Healthineers (Siemens AG)
• Danaher Corporation (Beckman Coulter, Cepheid, Radiometer)
• Thermo Fisher Scientific Inc.
• BD (Becton, Dickinson and Company)
• bioMérieux SA
• QuidelOrtho
• Johnson & Johnson Services Inc.
• Nova Biomedical

Sources and Research References

• Company annual reports, product catalogs, and institutional procurement disclosures from 2024 to 2025.
• Government health ministry publications, regulatory agency databases, and institutional accreditation body reports.
• Industry association data, trade publications, and healthcare equipment procurement records.
• National and regional healthcare infrastructure investment reports, clinical adoption studies, and market access assessments.
• Primary interviews with institutional buyers, clinicians, procurement officers, manufacturers, and distributors.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Point of Care Diagnostics Market?
• How fast is the Point of Care Diagnostics Market expected to grow between 2026 and 2036?
• Which product segment is likely to lead the market by 2026?
• Which application segment is expected to account for the highest demand by 2026?
• What factors are driving demand globally?
• How is the shift toward digitally connected systems influencing the market?
• Why is India emerging as one of the fastest-growing markets?
• How are government healthcare programs supporting procurement demand?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in India and China?
• Who are the key companies active in the Point of Care Diagnostics Market?
• How does Fact.MR estimate and validate the market forecast?

Point of Care Diagnostics Market Definition

The point of care diagnostics market covers glucose monitoring systems, acute care diagnostics, and associated equipment and consumables used across institutional, clinical, and field-based care settings. It includes products and systems deployed across hospitals, specialty clinics, ambulatory care centers, and government health programs globally.

Point of Care Diagnostics Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, application, end use, technology, and region.
• It includes regional demand analysis across major geographies, based on institutional procurement, regulatory standards, clinical adoption rates, and healthcare infrastructure investment.
• The report includes pricing and cost analysis across entry-level, mid-range, and premium product tiers, covering both capital equipment and recurring consumable components.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, pricing strategy, geographic reach, and distribution positioning of leading companies.

Point of Care Diagnostics Market Exclusions

• The scope excludes general-purpose equipment not specifically designed or classified for point of care diagnostics applications.
• It excludes standalone software platforms, mobile applications, and analytics tools sold without hardware components.
• The report excludes custom-built, non-commercial systems without market-facing sales activity.
• It also excludes informal unbranded products, rental-only services without equipment sales, and legacy systems no longer in active production.

Point of Care Diagnostics Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 60+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• Key inputs include institutional procurement data, clinical adoption rates, regulatory approval timelines, and healthcare infrastructure investment patterns.
• The model cross-checks demand with shipment volumes, pricing trends, channel mix, and product launch timelines.
• Primary validation includes 25+ interviews across manufacturers, distributors, institutional buyers, clinicians, and procurement officials.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.